Home/Pipeline/Twymeeg (nemolizumab)

Twymeeg (nemolizumab)

Pruritus in Atopic Dermatitis

FiledUnder Regulatory Review

Key Facts

Indication
Pruritus in Atopic Dermatitis
Phase
Filed
Status
Under Regulatory Review
Company

About Galderma

Galderma's mission is to advance dermatology for every skin story, establishing itself as the world's most trusted leader in skin health. The company has achieved this through a resilient, tri-segment business model, a robust R&D engine, and a successful 2024 IPO that marked Europe's largest of the year. Its strategy centers on driving growth through innovation in its core aesthetics and prescription franchises, expanding its consumer care reach, and leveraging its global commercial infrastructure to maintain a competitive edge in the dynamic dermatology market.

View full company profile

About Galderma

Galderma's mission is to advance dermatology for every skin story, establishing itself as the world's most trusted leader in skin health. The company has achieved this through a resilient, tri-segment business model, a robust R&D engine, and a successful 2024 IPO that marked Europe's largest of the year. Its strategy centers on driving growth through innovation in its core aesthetics and prescription franchises, expanding its consumer care reach, and leveraging its global commercial infrastructure to maintain a competitive edge in the dynamic dermatology market.

View full company profile

Other Pruritus in Atopic Dermatitis Drugs

DrugCompanyPhase
CBP-174Connect BiopharmaPhase 2